- Trial phase
- Phase 1b/2a (pMN study by Everest Medicines); pre-IND for Travere's planned trials
- Time to market
- Years away. Travere plans to file a U.S. IND by year-end 2026 and initiate late-stage studies, meaning pivotal readouts and any potential approval would be several years out, likely in the 2029-2031 timeframe if successful.
- Why 3/10
- The next catalyst is the U.S. IND submission planned by year-end 2026, a procedural regulatory milestone rather than a high-impact binary event. No pivotal readout or PDUFA date is scheduled within the next 12 months, and civorebrutinib is one of several pipeline programs at a company with an already-approved commercial product (FILSPARI).
Travere plans to submit a U.S. IND for civorebrutinib by year-end 2026, which would enable dosing studies. Look for IND acceptance and initial Phase 2 trial initiation in 2027. Pivotal readouts are likely years away. The stock's near-term catalysts remain FILSPARI sales execution and the Phase 3 HARMONY pegtibatinase topline data (expected 2H 2027).
Price Chart
Executive Summary
Civorebrutinib (also known as EVER001/XNW1011) is an investigational oral, covalent reversible Bruton's tyrosine kinase (BTK) inhibitor that Travere Therapeutics in-licensed from Everest Medicines in June 2026 for $112.5 million upfront, with up to $1.03 billion in potential milestones. The drug has shown proof of concept in a Phase 1b/2a trial for primary membranous nephropathy (pMN), demonstrating rapid reductions in anti-PLA2R autoantibodies (up to 93%) and proteinuria (78%) sustained through 52 weeks. Travere plans to submit a U.S. IND by year-end 2026 and advance the drug into late-stage studies across pMN, immune-mediated FSGS, and minimal change disease. However, the program remains early-stage (pre-pivotal), and no high-impact binary catalyst is scheduled within the next 12 months; the stock's near-term value is primarily driven by the approved product FILSPARI (sparsentan), which generated $200 million in Q3 2026 sales.
How It Works
Civorebrutinib blocks an enzyme called Bruton's tyrosine kinase (BTK), which is essential for the survival and activity of B cells, a type of immune cell. By inhibiting BTK, the drug reduces the production of harmful autoantibodies that attack the kidneys in certain immune-mediated kidney diseases. Unlike some older BTK inhibitors, it binds reversibly (not permanently), which may improve safety.
Trial Status
Everest Medicines completed a Phase 1b/2a open-label trial in China for primary membranous nephropathy (pMN). Data showed up to 93% reduction in anti-PLA2R autoantibodies at week 24 and 78% reduction in proteinuria sustained through 52 weeks, with a well-tolerated safety profile. Travere in-licensed global rights (ex-China and certain East/Southeast Asian countries) in June 2026 and plans to submit a U.S. IND by year-end 2026 to enable its own dosing studies across pMN, immune-mediated FSGS, and minimal change disease (MCD).
The Two-Sided Case
Upcoming Catalysts
- U.S. IND submission planned by year-end 2026
- Initiation of Travere-sponsored Phase 2/3 studies in pMN, FSGS, and/or MCD (expected 2027)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Travere Therapeutics, Inc. 8-K TVTX ·Originating report